Get the Stockscreener App
66.24
0.12%
0.08
After Hours:
66.24
Merus N V stock is traded at $66.24, with a volume of 845.08K.
It is up +0.12% in the last 24 hours and up +25.93% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$66.16
Open:
$65.54
24h Volume:
845.08K
Relative Volume:
0.77
Market Cap:
$4.58B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-16.77
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.84%
1M Performance:
+25.93%
6M Performance:
+61.80%
1Y Performance:
+24.89%
1-Day Range:
$65.16
$67.59
1-Week Range:
$63.75
$67.59
52-Week Range:
$33.19
$67.59
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
66.24 | 4.93B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
10 Best All-Time High Stocks to Buy According to Analysts - Insider Monkey
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment - TipRanks
How volatile is Merus N.V. stock compared to the marketSwing Trade Updates To Watch Now - jammulinksnews.com
Merus N.V. Flashes Buy Signal on Multi Timeframe ChartWeekly Setup With 3x Return Potential Published - metal.it
What makes Merus N.V. stock price move sharplyConsistent Income Focused Trade List Analyzed - metal.it
Options Data Show Bullish Bias in Merus N.V.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
RSI Crosses Above 30 for Merus N.V. — Reversal in SightShort Term Setup With Predictive Chart Confirmed - metal.it
When is Merus N.V. stock expected to show significant growthStock Market Opportunities For Every Investor - jammulinksnews.com
Why is Merus N.V. stock attracting strong analyst attentionGrow your portfolio with growth-oriented stocks - jammulinksnews.com
What institutional investors are buying Merus N.V. stockFree Daily Trading Room Entry - jammulinksnews.com
What is the risk reward ratio of investing in Merus N.V. stockCapitalize on market trends early - jammulinksnews.com
What are Merus N.V. company’s key revenue driversRapid wealth creation - jammulinksnews.com
Should I hold or sell Merus N.V. stock in 2025Massive profits - jammulinksnews.com
Is it the right time to buy Merus N.V. stockMassive profits - jammulinksnews.com
Merus NV stock reaches all-time high at 66.44 USD By Investing.com - Investing.com South Africa
Merus NV stock reaches all-time high at 66.44 USD - Investing.com
Why Merus N.V. stock is on top investor watchlistsHigh-impact stock picks - jammulinksnews.com
How high can Merus N.V. stock price go in 2025Breakout stock performance - jammulinksnews.com
Merus N.V. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
What analysts say about Merus N.V. stockDynamic growth stocks - jammulinksnews.com
What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional
Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional
Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest
Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com
Merus Shares Surge Amid Promising Cancer Study - TipRanks
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):